Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors

NCT03398720 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult

Interventions

DRUG: HTI-1066 dose level 1
DRUG: HTI-1066 dose level 2
DRUG: HTI-1066 dose level 3
DRUG: HTI-1066 dose level 4

Sponsor

Jiangsu HengRui Medicine Co., Ltd.